Show simple item record

dc.contributor.authorCruz, Israel 
dc.contributor.authorAlbertini, Audrey
dc.contributor.authorBarbeitas, Mady
dc.contributor.authorArana, Byron
dc.contributor.authorPicado, Albert
dc.contributor.authorRuiz-Postigo, Jose A
dc.contributor.authorNdung'u, Joseph M
dc.date.accessioned2019-05-21T08:56:56Z
dc.date.available2019-05-21T08:56:56Z
dc.date.issued2019-05
dc.identifier.citationParasite Epidemiol Control. 2019 Mar 7;5:e00103.es_ES
dc.identifier.issn24056731es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7624
dc.description.abstractObjectives: Localized cutaneous leishmaniasis and its evolving forms diffuse cutaneous leishmaniasis, mucosal leishmaniasis and cutaneous leishmaniasis recidivans, together with the visceral leishmaniasis sequelae post-kala azar dermal leishmaniasis account for about one million dermal leishmaniases cases per year worldwide. Although not lethal, the dermal leishmaniases cause chronic and disfiguring skin lesions, which are an important cause of morbidity and stigma.Microscopy remains the reference test for diagnosis of dermal leishmaniasis; however, it has low and variable sensitivity and requires well trained personnel. The technical complexity and cost of the more sensitive molecular techniques (e.g. PCR) limits their application in routine diagnosis in endemic areas. Point-of-care (POC) tests for early diagnosis are much needed in order to benefit both patients and communities, by reducing the risk of both sequelae and Leishmania transmission. To this end we developed a Target Product Profile (TPP) for a POC test for dermal leishmaniases. Methods: The TPP was defined through several rounds of discussions and by consensus with stakeholders and experts in dermal leishmaniases from different type of organizations and endemic regions. Results and conclusions: A rapid, simple and robust test that can be implemented in resource-limited settings, enabling decentralized diagnosis and treatment of dermal leishmaniasis should be developed. Ideally it should enable the diagnosis of all forms of dermal leishmaniasis, but the minimally accepted target would be localized cutaneous leishmaniasis. A minimum sensitivity of 95% and specificity of 90% would be required. The consensus was that the POC test should target Leishmania antigens.es_ES
dc.description.sponsorshipWe would like to thank all experts and colleagues involved in the consultations, the animated discussions during the meetings of experts and online reviews, the useful comments and contributions to the different features of the TPP. UK aid from the UK Government, and the Government of Switzerland contributed to FIND's participation in this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscriptes_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCutaneous leishmaniasises_ES
dc.subjectDermal leishmaniasises_ES
dc.subjectLeishmaniasises_ES
dc.subjectPoint-of-care diagnosticses_ES
dc.subjectTarget Product Profilees_ES
dc.titleTarget Product Profile for a point-of-care diagnostic test for dermal leishmaniaseses_ES
dc.typeArtículoes_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID30923755es_ES
dc.format.volume5es_ES
dc.format.pagee00103es_ES
dc.identifier.doi10.1016/j.parepi.2019.e00103es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2405-6731es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.parepi.2019.e00103es_ES
dc.identifier.journalParasite epidemiology and controles_ES
dc.repisalud.centroISCIII::Escuela Nacional de Sanidades_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional